Advertisement
Singapore markets open in 7 hours 45 minutes

  • Straits Times Index

    3,296.89
    +4.20 (+0.13%)
     

  • S&P 500

    5,049.74
    +31.35 (+0.62%)
     

  • Dow

    38,134.44
    +231.15 (+0.61%)
     

  • Nasdaq

    15,773.73
    +168.24 (+1.08%)
     

  • Bitcoin USD

    59,099.12
    +2,346.75 (+4.14%)
     

  • CMC Crypto 200

    1,272.39
    +1.65 (+0.13%)
     

  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     

  • Gold

    2,310.90
    -0.10 (-0.00%)
     

  • Crude Oil

    79.08
    +0.08 (+0.10%)
     

  • 10-Yr Bond

    4.5930
    -0.0020 (-0.04%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,207.13
    +444.10 (+2.50%)
     

  • FTSE Bursa Malaysia

    1,580.30
    +4.33 (+0.27%)
     

  • Jakarta Composite Index

    7,117.42
    -116.77 (-1.61%)
     

  • PSE Index

    6,646.55
    -53.94 (-0.81%)
     

Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of February 29th, 2024

Business Wire
·1-min read

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France, March 08, 2024--(BUSINESS WIRE)--Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

18,404,608

Number of real voting rights*

(excluding treasury shares**)

18,347,480

Theoretical number of voting rights*

(including treasury shares**)

18,381,408

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer and metabolic disease diagnoses and treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. Since its inception, the French-based company, with a presence in the U.S. and China, has been recognized as an "Innovative company" by BPI France and trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240308862631/en/

Contacts

Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press - ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com